Company Shares of InspireMD (NYSEMKT:NSPR) Drops by -21.5%

InspireMD (NYSEMKT:NSPR) : During the past 4 weeks, traders have been relatively bearish on InspireMD (NYSEMKT:NSPR), hence the stock is down -54.59% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -22.49% relative to the S&P 500. The 4-week change in the price of the stock is -53.85% and the stock has fallen -21.5% in the past 1 week.

The company shares have dropped -91.67% from its 1 Year high price. On Aug 6, 2015, the shares registered one year high at $3.10 and the one year low was seen on Jul 8, 2016. The 50-Day Moving Average price is $0.37 and the 200 Day Moving Average price is recorded at $0.52.

The stock has recorded a 20-day Moving Average of 42.46% and the 50-Day Moving Average is 50.52%.


InspireMD (NYSEMKT:NSPR): On Fridays trading session , Opening price of the stock was $0.23 with an intraday high of $0.23. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.1995. However, the stock managed to close at $0.2012, a loss of 12.48% for the day. On the previous day, the stock had closed at $0.2299. The total traded volume of the day was 1,315,802 shares.

In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Inspiremd, Inc., Loughlin James J, had purchased 50,000 shares in a transaction dated on March 21, 2016. The transaction was executed at $0.59 per share with total amount equaling $29,500.

InspireMD, Inc. is a medical device company. The Company is focused on the development and commercialization of its MicroNet stent platform technology for the treatment of complex coronary and vascular disease. The Companys MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. The Companys MGuard coronary products combining MicroNet and a bare-metal stent (MGuard Prime Embolic Protection Stent (EPS)) are marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The Companys second product CGuard carotid embolic prevention system (EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease. The Company is also developing a pipeline of other products and additional applications by leveraging its MicroNet technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.